Qiagen NV Dossier
Qualitative Analysis
Business overview
QIAGEN N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. The company's proprietary technologies isolate and purify DNA, RNA, and proteins (Sample technologies), amplify and enrich these biomolecules (Assay technologies), and analyze and interpret the results using advanced bioinformatics (Digital Insights). QIAGEN serves more than 500,000 customers worldwide across two primary markets: Molecular Diagnostics (clinics, hospitals, and testing laboratories) and Life Sciences (academia, pharmaceutical research, and applied testing). Consumables and related revenues represent approximately 90% of total sales, providing a highly resilient, recurring revenue stream, with the remaining 10% derived from instrumentation and services.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing investments and commercialization efforts on five core growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics, and QuantiFERON latent tuberculosis testing [1.2.2].
Expected impact: Aims to achieve at least $2 billion in combined annual sales from these five pillars by 2028.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand QIAGEN's Sample technologies portfolio into highly scalable single-cell analysis using Parse's instrument-free Evercode chemistry [1.2.2].
Financial impact: Forecasted to generate over $40 million in revenues for QIAGEN in 2026.
To acquire Franklin, Genoox's flagship cloud-based community platform, and integrate AI-powered software for scaling and speeding up the processing of complex genetic tests within the QIAGEN Digital Insights portfolio.
Financial impact: Expected to generate approximately $5 million of sales in 2025 with a neutral impact on adjusted EPS.
Strategic Partnerships
Integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases to help researchers identify disease mechanisms, therapeutic targets, and biomarkers with greater speed and confidence [2.2.3].
Terms: Not disclosed; initial pilot programs are available to select pharmaceutical and biotechnology partners.
To develop and commercialize a kit-based version of Foresight's CLARITY NGS assay for ultra-sensitive minimal residual disease (MRD) detection in lymphoma and other hematological malignancies.
Terms: Not disclosed.
To co-develop oncology assays for the QIAcuityDx digital PCR platform, expanding the range of in vitro diagnostic assays available for clinical diagnostics.
Terms: Not disclosed.
To connect advanced track-based laboratory automation with the QuantiFERON latent TB testing workflow, enabling a seamless end-to-end automated workflow for high-throughput laboratories.
Terms: Not disclosed.